Abstract 141P
Background
In early March 2020, after the WHO announced a pandemic caused by the highly contagious pathogen SARS CoV-2 (COVID-19), medical institutions were forced to reduce the number of visit including for cancer patients.
Methods
Analysis of colon cancer (CC) epidemiological indicators of RC from Kazakhstan Cancer Registry in period 2017 – 2022 and impact of COVID-19 pandemic restrictions in 2020. Standardized indicators per 100,000 population (‰) were calculated by World 2001 standard.
Results
Incidence per 100,000 population decreased by 2.2% from 8.9 ‰ in 2017 to 8.7 ‰ in 2022. During COVID-19 restrictions, the incidence was 7.8 ‰ in 2020, which is 4.9% lower than in 2019, and the same as in 2021. Mortality per 100,000 population decreased by 23.7%, from 3.8 ‰ at 2017 year to 2.9 ‰ at 2022 year. During COVID-19 restrictions, mortality was 3.6 ‰ in 2020, which is 2.9% higher than in 2019, and 13.9% higher than in 2021.The ratio of mortality to incidence decreased by 9.4 (decrease rate by 22.0%), from 42.7 at 2017 year to 33.3 at 2022 year. During COVID-19 restrictions, the ratio of mortality to incidence was 46.2, which is 8.2% higher than in 2019, and 14.1% higher than in 2021.One-year mortality decreased by 3.3% (decline rate by 15.1%), from 21.9% at 2017 year to 18.6% at 2022 year. During COVID-19 restrictions, the one-year mortality was 19.8%. During COVID-19 restrictions, the overall mortality for all patients under follow-up observation was 8.9%, which is 2.3% higher than in 2019, and 13.5% higher than in 2021. 5-year survival increased on 8.0% (growth rate by 17.9%), from 44.7% at 2017 year to 52.7% at 2022 year. This is a long-term indicator that reacts delayed, before COVID-19 restrictions, it increased more progressively by 6.0%, a growth rate of 13.4%. after COVID-19 restrictions, 5-year survival increased less progressively by 2.0%, a growth rate of 3.9%. CC early/advance stage ratio has not changed, from 1.1 at 2017 year to 1.1 at 2022 year. During COVID-19 restrictions early/advance stage ratio was 1.1, and decreased from 1.3 in 2019 to 1.1 in 2021, which indicates a deterioration in detection in the early stages during the period of COVID-19 restrictions by 15.4%.
Conclusions
Epidemiological indicators colon cancer have worsened during the COVID pandemic.
Clinical trial identification
AP13068657.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.